Compare Avient Corporation (AVNT) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Humana Inc — how do they compare? Avient Corporation trades at $45.2 (market cap $4.17B), while Humana Inc trades at $374.25 (market cap $44.77B). The key difference: Humana Inc is far larger — about 10.7× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AVNT | HUM | |
|---|---|---|
Market Cap | $4.17B | $44.77B |
Sector | Technology | Health |
52-Week High | $45.69 | $409.42 |
52-Week Low | $27.48 | $163.67 |
Enterprise Value | $5.62B | $52.12B |
Dividend Yield | 2.42% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $45.1, down 1.2% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue remains stable at $3.3 billion, with a net income margin improving to 5.1% in 2026. Analysts maintain a Buy consensus with a $49 price target, reflecting optimism about continued growth and dividend stability.
The stock offers upside potential from earnings momentum and a solid dividend yield, but faces risks from macroeconomic pressures on materials demand and high RSI levels suggesting overbought conditions. Institutional sentiment is positive, with no Sell ratings, though investors should monitor debt levels and competitive dynamics in the chemical sector for sustained performance.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
